Patent ID: 11918629
Assignee: OMRIX BIOPHARMACEUTICALS LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 8:
9. A two-component composition for use in preventing tissue adhesion, comprising:
component A comprising: a plasma cryoprecipitate-containing solution comprising fibrinogen at a concentration range of about 10 mg/ml to about 25 mg/ml, and a total protein concentration range of about 15 mg/ml to about 40 mg/ml, wherein the fibrinogen is in a range of about 50% to less than 80% of total protein by weight; and component B comprising thrombin; wherein:
component A comprises albumin at a concentration ranging from 1.2 mg/ml up to about 1.53 mg/ml; wherein component A and/or component B comprises free calcium ions, and wherein the cryoprecipitate is depleted from plasmin and/or plasminogen, does not comprise tranexamic acid or aprotinin, and comprises factor XIII, fibronectin, and optionally one or more members selected from factor VIII, von Willebrand factor (vWF), and vitronectin.